Catherine Skari
-
Sep- 2022 -2 SeptemberScientific Literature
Precision Medicine and Sickle Cell Disease
Sickle cell disease (SCD) is characterized by variable clinical outcomes, with some patients suffering life-threatening complications during childhood, and others…
Read More » -
Aug- 2022 -30 AugustScientific Literature
Does Hepcidin Tuning Have a Role Among Emerging Treatments for Thalassemia?
The treatments available for thalassemia are rapidly evolving, with major advances made in gene therapy and the modulation of erythropoiesis.…
Read More » -
29 August
-
29 AugustNews
SICKLE CELL DISEASE | African Health Ministers Launch Drive to Curb SCD’s Toll
This effort, backed by the African Regional Office of the World Health Organization (WHO), aims to curb SCD΄s toll in…
Read More » -
26 AugustNews
A HISTORIC BREAKTHROUGH | UNICEF Signs First-Ever Malaria Vaccine Supply Contract With GSK
The contract will enable UNICEF to deliver more than 18 million doses of the RTS,S vaccine – also known under…
Read More » -
25 AugustScientific Literature
In Vivo Base Editing by a Single Intravenous Vector Injection for Treatment of Hemoglobinopathies
Individuals with β-thalassemia or Sickle Cell Disease and hereditary persistence of fetal hemoglobin (HPFH) possessing 30% HbF appear to be…
Read More » -
22 AugustScientific Literature
Luspatercept for the Treatment of Anaemia in Non-Transfusion-Dependent β-Thalassaemia (BEYOND): A Phase 2, Randomised, Double-blind, Multicentre, Placebo-controlled Trial
Background In patients with non-transfusion-dependent β-thalassaemia, haemoglobin concentrations lower than 10 g/dL are associated with a higher risk of morbidity,…
Read More » -
22 AugustScientific Literature
Luspatercept for the Treatment of Anaemia in Non-Transfusion-Dependent β-Thalassaemia (BEYOND): A Phase 2, Randomised, Double-blind, Multicentre, Placebo-controlled Trial
Background In patients with non-transfusion-dependent β-thalassaemia, haemoglobin concentrations lower than 10 g/dL are associated with a higher risk of morbidity, mortality, and…
Read More » -
17 AugustNews
BREAKING NEWS | Bluebird’s Gene Therapy For β-Thalassaemia Wins US Approval
The green light is “monumental” for both patients and the company itself, Tom Klima, Bluebird’s Chief Commercial Officer, said in…
Read More » -
14 AugustScientific Literature
Nutritional Status in a Sample of Patients With β-Thalassemia Major
Patients suffering from thalassemia have decreased levels of lean body mass and an increased nutritional risk. The aim of this…
Read More »
